Cargando…
Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination
Coronavirus Disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is frequently complicated by thrombosis. In some cases of severe COVID-19, fibrinolysis may be markedly enhanced within a few days, resulting in fatal bleeding. In the treatment of COVID...
Autores principales: | Yamada, Shinya, Asakura, Hidesaku |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955234/ https://www.ncbi.nlm.nih.gov/pubmed/35328761 http://dx.doi.org/10.3390/ijms23063338 |
Ejemplares similares
-
Perspective on fibrinolytic therapy in COVID-19: the potential of inhalation therapy against suppressed-fibrinolytic-type DIC
por: Asakura, Hidesaku, et al.
Publicado: (2020) -
COVID-19-associated coagulopathy and disseminated intravascular coagulation
por: Asakura, Hidesaku, et al.
Publicado: (2020) -
Blue Rubber Bleb Nevus Syndrome Complicated by Enhanced-Fibrinolytic-Type DIC: A Case Report
por: Yamada, Shinya, et al.
Publicado: (2021) -
A Pathophysiological Perspective on the SARS-CoV-2 Coagulopathy
por: Kusadasi, Nuray, et al.
Publicado: (2020) -
Pathophysiology of trauma-induced coagulopathy: disseminated intravascular coagulation with the fibrinolytic phenotype
por: Hayakawa, Mineji
Publicado: (2017)